Close

GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation (“Alcami”), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison Dearborn Partners (“MDP”) and Ampersand Capital Partners (“Ampersand”).

Headquartered in North Carolina, Alcami operates five campuses across the United States, which support sterile fill-finish and oral solid dose drug product manufacturing; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals, and materials.

Patrick Walsh, Chairman and CEO of Alcami, welcomes Jim Datin, Mike Mortimer, Alan MacKay, Jonathon Maschmeyer, Natasha Latif, and Bill Sharbaugh to the Alcami Board of Directors.

GHO Capital and The Vistria Group have acquired a 50/50 controlling interest in Alcami from funds affiliated with MDP and Ampersand. Ampersand and Alcami Management have reinvested significant equity as part of the acquisition. The financial terms of the transaction were not disclosed.

 

Latest stories

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back